The therapeutic potential of targeting barf1 in EBV-associated malignancies

Angela Kwok Fung Lo, Christopher W. Dawson, Hong Lok Lung, Ka-Leung Wong*, Lawrence S. Young*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)


Epstein-Barr virus (EBV) is closely linked to the development of a number of human cancers. EBV-associated malignancies are characterized by a restricted pattern of viral latent protein expression which is sufficient for the virus to both initiate and sustain cell growth and to protect virus-infected cells from immune attack. Expression of these EBV proteins in malignant cells provides an attractive target for therapeutic intervention. Among the viral proteins expressed in the EBV-associated epithelial malignancies, the protein encoded by the BamHI-A rightward frame 1 (BARF1) is of particular interest. BARF1 is a viral oncoprotein selectively expressed in latently infected epithelial cancers, nasopharyngeal carcinoma (NPC) and EBV-positive gastric cancer (EBV-GC). Here, we review the roles of BARF1 in oncogenesis and immunomodulation. We also discuss potential strategies for targeting the BARF1 protein as a novel therapy for EBV-driven epithelial cancers.

Original languageEnglish
Article number1940
Pages (from-to)1-12
Number of pages12
Issue number7
Publication statusPublished - 17 Jul 2020

Scopus Subject Areas

  • Oncology
  • Cancer Research

User-Defined Keywords

  • BARF1
  • EBV
  • EBV-associated cancers
  • Immunotherapy
  • Peptide therapy


Dive into the research topics of 'The therapeutic potential of targeting barf1 in EBV-associated malignancies'. Together they form a unique fingerprint.

Cite this